- Radiopharm Theranostics Limited reported a **20.2% decrease** in loss from ordinary activities after tax, totaling **($36,703,089)** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Revenue from contracts with customers significantly increased by **1114.3%** to **$3,633,422** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Net assets grew to **$42,871,904** and cash reserves to **$29,116,835** as of **June 30, 2025**, primarily due to capital raises.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:3]** 
- The company increased its ownership in Radiopharm Ventures from 51% to **75%** on **August 26, 2024**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- The financial statements for the year ended **June 30, 2025**, are currently undergoing audit, with the final audited report anticipated by mid-September 2025.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]**

Radiopharm Theranostics (RADX)